Transmedics Group Inc(TMDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 17.46 | EPS (ttm) | 3.84 | Insider Own | 3.86% | Shs Outstand | 34.6M | Perf Week | -6.86% |
| Market Cap | 2.33B | Forward P/E | 29.69 | EPS next Y | 54.25% | Insider Trans | -0.62% | Shs Float | 33.3M | Perf Month | -19.57% |
| Enterprise Value | 2.72B | PEG | - | EPS next Q | 0.3 | Inst Own | 104.96% | Short Float | 26.3% | Perf Quarter | -12.27% |
| Income | 0.15B | P/S | 3.48 | EPS this Y | -69.91% | Inst Trans | -5.02% | Short Ratio | 10.49 | Perf Half Y | -33.41% |
| Sales | 0.67B | P/B | 4.49 | EPS next 5Y | -13.19% | ROA | 12.88% | Short Interest | 8.77M | Perf YTD | -44.83% |
| Book/sh | 14.96 | P/C | 4.92 | EPS past 3/5Y | - | ROE | 36.28% | 52W High | -56.97% ($156.00) | Perf Year | -50.03% |
| Cash/sh | 13.63 | P/FCF | 29.45 | Sales past 3/5Y | 86.42% 88.21% | ROIC | 11.14% | 52W Low | 11.67% ($60.10) | Perf 3Y | 76.77% |
| Dividend Est. | - | EV/EBITDA | 23.07 | EPS Y/Y TTM | 108.84% | Gross Margin | 57.75% | Volatility(W/M) | 4.02% 5.12% | Perf 5Y | 144.7% |
| Dividend TTM | - | EV/Sales | 4.07 | Sales Y/Y TTM | 25.82% | Oper. Margin | 12.21% | ATR (14) | 3.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.07 | EPS Q/Q | -55.84% | Profit Margin | 22.69% | RSI (14) | 30.4 | Recom | 1.77 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.62 | Sales Q/Q | 20.7% | SMA20 | -10.33% ($74.85) | Beta | 2.09 | Target Price | $98.73 |
| Payout | - | Debt/Eq | 1.67 | Earnings | 2026/11/5 | SMA50 | -18.3% ($82.15) | Rel Volume | 1.19 | Prev Close | $66.9 |
| Employees | 898 | LT Debt/Eq | 1.63 | EPS/Sales Surpr. | -11.2% 3.23% | SMA200 | -29.24% ($94.86) | Avg Volume(3M) | 0.84M | Price | $67.12 |
| IPO | 2019/5/2 | Option/Short | Yes/Yes | Trades | 13567 | Volume | 991,428 | Change | 0.33% |
🫀 This US medical device company develops organ preservation and transport technology for long-term transplantation. Rather than storing donated organs in cold storage, its innovative system preserves and transports them in a living, functioning state, increasing the utilization of livers, hearts, and lungs for transplantation. The company offers an integrated transplant solution that combines organ preservation equipment, consumables, and a transport logistics network.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded about as much as usual. That is 119% of its average volume.
Next earnings report: November 5
6 days to go.
TMDX makes money exceptionally well
Of every $100 in sales, $12.21 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -69.9% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $2,307. Peers typically go for $1,750. Compared with its own 2-year average, it is 71% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +144.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Short interest is a burden
26.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 142 in the industry
Based on market cap of $2B.
ALMR#26 Alamar Biosciences Inc $2B PER - TMDX#27 Transmedics Group Inc $2B PER 17.5 
UFPT#28 UFP Technologies Inc $2B PER 31.6 
INSP#29 Inspire Medical Systems Inc $2B PER 15.5 
ESTA#30 Establishment Labs Holdings Inc $2B PER - 
FAQ
What kind of company is TMDX?
TMDX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TMDX?
The market cap of TMDX is approximately $2.3B, ranking 1,950 within its sector.
What is the P/E ratio of TMDX?
TMDX has a P/E ratio of approximately 17.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TMDX?
TMDX has recorded a 52-week high of $156.00 and a low of $60.10.
